# EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

> **NCT05498389** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 115 (estimated)

## Conditions studied

- Metastatic Lung Non-Small Cell Carcinoma
- Advanced Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- EGFR Mutation-Related Tumors

## Interventions

- **DRUG:** EMB-01
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05498389
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06
- **Primary completion:** 2024-07
- **Final completion:** 2024-12
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05498389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05498389, "EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05498389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*